843 related articles for article (PubMed ID: 33212758)
1. The Role of α-Synuclein Oligomers in Parkinson's Disease.
Du XY; Xie XX; Liu RT
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33212758
[TBL] [Abstract][Full Text] [Related]
2. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease.
Rocha EM; De Miranda B; Sanders LH
Neurobiol Dis; 2018 Jan; 109(Pt B):249-257. PubMed ID: 28400134
[TBL] [Abstract][Full Text] [Related]
3. Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production.
Tapias V; Hu X; Luk KC; Sanders LH; Lee VM; Greenamyre JT
Cell Mol Life Sci; 2017 Aug; 74(15):2851-2874. PubMed ID: 28534083
[TBL] [Abstract][Full Text] [Related]
4. Role of α-synuclein in neurodegeneration: implications for the pathogenesis of Parkinson's disease.
Yu S; Chan P
Essays Biochem; 2014; 56():125-35. PubMed ID: 25131591
[TBL] [Abstract][Full Text] [Related]
5. Intermediates of α-synuclein aggregation: Implications in Parkinson's disease pathogenesis.
Gadhe L; Sakunthala A; Mukherjee S; Gahlot N; Bera R; Sawner AS; Kadu P; Maji SK
Biophys Chem; 2022 Feb; 281():106736. PubMed ID: 34923391
[TBL] [Abstract][Full Text] [Related]
6. Modulating α-synuclein propagation and decomposition: Implications in Parkinson's disease therapy.
Li B; Xiao X; Bi M; Jiao Q; Chen X; Yan C; Du X; Jiang H
Ageing Res Rev; 2024 Jul; 98():102319. PubMed ID: 38719160
[TBL] [Abstract][Full Text] [Related]
7. Beyond α-synuclein transfer: pathology propagation in Parkinson's disease.
Hansen C; Li JY
Trends Mol Med; 2012 May; 18(5):248-55. PubMed ID: 22503115
[TBL] [Abstract][Full Text] [Related]
8. Common Mechanisms Underlying α-Synuclein-Induced Mitochondrial Dysfunction in Parkinson's Disease.
Sohrabi T; Mirzaei-Behbahani B; Zadali R; Pirhaghi M; Morozova-Roche LA; Meratan AA
J Mol Biol; 2023 Jun; 435(12):167992. PubMed ID: 36736886
[TBL] [Abstract][Full Text] [Related]
9. Metabotropic glutamate receptor 5 inhibits α-synuclein-induced microglia inflammation to protect from neurotoxicity in Parkinson's disease.
Zhang YN; Fan JK; Gu L; Yang HM; Zhan SQ; Zhang H
J Neuroinflammation; 2021 Jan; 18(1):23. PubMed ID: 33461598
[TBL] [Abstract][Full Text] [Related]
10. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
Sahay S; Ghosh D; Singh PK; Maji SK
Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
[TBL] [Abstract][Full Text] [Related]
11. The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease.
Lin KJ; Lin KL; Chen SD; Liou CW; Chuang YC; Lin HY; Lin TK
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731450
[TBL] [Abstract][Full Text] [Related]
12. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology.
Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA
Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232
[TBL] [Abstract][Full Text] [Related]
13. Baicalein inhibits α-synuclein oligomer formation and prevents progression of α-synuclein accumulation in a rotenone mouse model of Parkinson's disease.
Hu Q; Uversky VN; Huang M; Kang H; Xu F; Liu X; Lian L; Liang Q; Jiang H; Liu A; Zhang C; Pan-Montojo F; Zhu S
Biochim Biophys Acta; 2016 Oct; 1862(10):1883-90. PubMed ID: 27425033
[TBL] [Abstract][Full Text] [Related]
14. Differential inhibition of α-synuclein oligomeric and fibrillar assembly in parkinson's disease model by cinnamon extract.
Shaltiel-Karyo R; Davidi D; Frenkel-Pinter M; Ovadia M; Segal D; Gazit E
Biochim Biophys Acta; 2012 Oct; 1820(10):1628-35. PubMed ID: 22575665
[TBL] [Abstract][Full Text] [Related]
15. α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies.
Prots I; Grosch J; Brazdis RM; Simmnacher K; Veber V; Havlicek S; Hannappel C; Krach F; Krumbiegel M; Schütz O; Reis A; Wrasidlo W; Galasko DR; Groemer TW; Masliah E; Schlötzer-Schrehardt U; Xiang W; Winkler J; Winner B
Proc Natl Acad Sci U S A; 2018 Jul; 115(30):7813-7818. PubMed ID: 29991596
[TBL] [Abstract][Full Text] [Related]
16. Lipid vesicles affect the aggregation of 4-hydroxy-2-nonenal-modified α-synuclein oligomers.
Sardar Sinha M; Villamil Giraldo AM; Öllinger K; Hallbeck M; Civitelli L
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3060-3068. PubMed ID: 29960040
[TBL] [Abstract][Full Text] [Related]
17. Alpha-Synuclein: The Interplay of Pathology, Neuroinflammation, and Environmental Factors in Parkinson's Disease.
He S; Zhong S; Liu G; Yang J
Neurodegener Dis; 2020; 20(2-3):55-64. PubMed ID: 33465773
[TBL] [Abstract][Full Text] [Related]
18. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein oligomers: a new hope.
Bengoa-Vergniory N; Roberts RF; Wade-Martins R; Alegre-Abarrategui J
Acta Neuropathol; 2017 Dec; 134(6):819-838. PubMed ID: 28803412
[TBL] [Abstract][Full Text] [Related]
20. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
